Journal of Obstetrics and Gynaecology · 2013 · 14 citations · 11 references
MedicineMaternal HealthObstetricsObstetric ComplicationsPostpartum Hemorrhage ManagementReproductive MedicineIntrapartum ComplicationsPostpartum ComplicationsPostpartum HemorrhagePregnancyUterotonic TherapyComparative Effectiveness Of UterotonicsControl Group DesignIntramuscular OxytocinMatched Control GroupMaternal OxytocinMisoprostol TherapyOxytocin UseSublingual Misoprostol
This study aims to evaluate the efficacy and side-effects of 200 μg sublingual misoprostol vs 5 IU i.m. oxytocin, administered immediately following cord clamping in normal non-augmented vaginal delivery, in prevention of postpartum haemorrhage (PPH). A total of 104 women were randomised into three groups: misoprostol group (28 patients); oxytocin group (37 patients) and control group (39 patients). Misoprostol and oxytocin significantly minimised the blood loss during the third stage of labour and reduced the need for additional treatments for PPH as compared with the control group. Oxytocin was more effective than misoprostol in minimising blood loss and the need for additional uterotonic treatments. However, a significant decrease in systolic and diastolic blood pressure, associated with tachycardia was observed in the oxytocin group. In conclusion, sublingual misoprostol appears to be less effective than i.m. oxytocin in the prevention of PPH; however, it has the potential advantages of being easily used, cost-effective and stable at room temperature. Therefore, sublingual misoprostol is still a feasible drug for routine management of third stage, especially in areas with limited medical facilities.
11
Pharmacokinetics of different routes of administration of misoprostol
Human Reproduction · 2002 · 495 citations · Full text
Beverly Winikoff, Rasha Dabash, Jill Durocher et al. · The Lancet · 2010 · 127 citations
Medicine, Gynecology, Obstetrics +13